Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Sees Significant Growth in Short Interest

Posted by Francis Steltz on Oct 15th, 2026

Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) was the target of a large increase in short interest in September. As of September 30th, there was short interest totaling 935,276 shares, an increase of 83.9% from the September 15th total of 508,658 shares. Based on an average daily trading volume, of 41,326,353 shares, the short-interest ratio is currently 0.0 days. Approximately 8.8% of the company’s shares are sold short.

Insider Buying and Selling at Greenland Mines Ltd. Common Stock

In other Greenland Mines Ltd. Common Stock news, Director Jason David Sawyer bought 4,800 shares of the stock in a transaction that occurred on Wednesday, July 22nd. The stock was acquired at an average cost of $11.50 per share, with a total value of $55,200.00. Following the purchase, the director owned 4,800 shares in the company, valued at $55,200. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jeff Leblanc bought 14,000 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were bought at an average price of $9.72 per share, for a total transaction of $136,080.00. Following the completion of the acquisition, the chief financial officer directly owned 110,406 shares in the company, valued at approximately $1,073,146.32. This trade represents a 14.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Greenland Mines Ltd. Common Stock

A hedge fund recently bought a new stake in Greenland Mines Ltd. Common Stock stock. State Street Corp bought a new stake in Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 302,500 shares of the company’s stock, valued at approximately $79,000. State Street Corp owned approximately 9.51% of Greenland Mines Ltd. Common Stock as of its most recent filing with the Securities and Exchange Commission. 20.07% of the stock is owned by hedge funds and other institutional investors.

Greenland Mines Ltd. Common Stock Price Performance

GRML opened at $6.49 on Thursday. The business’s 50-day moving average price is $7.47 and its two-hundred day moving average price is $14.04. Greenland Mines Ltd. Common Stock has a 1 year low of $2.82 and a 1 year high of $36.99. The company has a market capitalization of $78.06 million, a price-to-earnings ratio of -0.56 and a beta of 6.26.

Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last issued its quarterly earnings results on Monday, August 17th. The company reported ($0.03) EPS for the quarter.

Greenland Mines Ltd. Common Stock declared that its board has initiated a share buyback program on Tuesday, October 6th that permits the company to repurchase $20.00 million in shares. This buyback authorization permits the company to reacquire up to 20.4% of its shares through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on GRML shares. Weiss Ratings cut shares of Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 9th. Wall Street Zen upgraded shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a report on Saturday, August 29th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Read Our Latest Research Report on GRML

Greenland Mines Ltd. Common Stock Company Profile

(Get Free Report)

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.